Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.19 USD

4.19
1,066,402

+0.24 (6.08%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $4.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up

by Zacks Equity Research

Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.

Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 4.17% and 4.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?

by Zacks Equity Research

Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases

by Zacks Equity Research

Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.

Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others

by Zacks Equity Research

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA

by Zacks Equity Research

With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder

by Zacks Equity Research

FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.

Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 3.70% and 2.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

by Zacks Equity Research

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance

by Zacks Equity Research

Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.

Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -32.26% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues

by Zacks Equity Research

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?

by Zacks Equity Research

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Indrajit Bandyopadhyay headshot

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

by Indrajit Bandyopadhyay

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Is Ironwood Pharmaceuticals (IRWD) a Suitable Stock for Value Investors?

by Zacks Equity Research

Is Ironwood Pharmaceuticals (IRWD) a great pick from the value investor's perspective right now? Read on to know more.